The effect of 1% pilocarpine mouthwash on salivation in patients undergoing head and neck radiotherapy: a double-blind randomized clinical trial
Phase 3
Recruiting
- Conditions
- Xerostomia.
- Registration Number
- IRCT20210830052335N1
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 62
Inclusion Criteria
Head and neck cancers. Topical laryngeal cancer, hypopharyngeal cancer and nasopharyngeal cancer
Under conventional radiation therapy with doses greater than 50 g
Satisfaction to participate in the study
Exclusion Criteria
Changes in the patient's treatment protocol or process of receiving radiation therapy
Lack of patient cooperation in the study process
Taking any medication that reduces salivation, physical
systemic diseases such as Sjogren's syndrome, diabetes, Behcet's disease, hypertension and hyperthyroidism
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Salivation rate. Timepoint: Two weeks before the first (basic) radiotherapy session, the first day of radiation therapy and two and four weeks after radiation therapy. Method of measurement: For this purpose, the spitting method will be used in which patients refrain from drinking or eating anything for 90 minutes before sampling. Then, for 5 minutes, people will be asked to empty their saliva into a calibrated test tube once or twice a minute. The amount of saliva (ml in 5 minutes) will be calculated and recorded.
- Secondary Outcome Measures
Name Time Method